Ucb Eulerpool Ziņas

Ucb Eulerpool News

Ucb Akciju Ziņas

Ucb tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Ucb ziņas mēs apkopojam šeit.

• 30. septembris ·

  Yahoo
  UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
• 30. septembris ·

  TipRanks
  Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
• 27. septembris ·

  Yahoo
  UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
• 25. septembris ·

  Yahoo
  UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
• 24. septembris ·

  Yahoo
  Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
• 24. septembris ·

  Seeking Alpha
  Biogen, UCB mark late-stage trial win for autoimmune disease therapy
• 24. septembris ·

  Yahoo
  UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
• 23. septembris ·

  Yahoo
  UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
• 23. septembris ·

  Seeking Alpha
  UCB gets expanded FDA approval for psoriasis drug Bimzelx
• 16. septembris ·

  TipRanks
  Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)